Predictors for Survival of Patients with Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Region.
carcinoma of unknown primary (CUP)
head and neck cancer
human papillomavirus (HPV)
oropharyngeal squamous cell carcinomas (OPSCC)
principal component analysis
risk model
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Apr 2023
06 Apr 2023
Historique:
received:
31
01
2023
revised:
26
02
2023
accepted:
17
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Human papillomavirus (HPV) status is the most important predictor of survival in oropharyngeal squamous cell carcinoma (OPSCC). In patients with cervical lymph node metastases of squamous cell carcinoma of unknown origin (CUP We assessed a consecutive cohort of CUP In 32/103 (31%) CUP Despite obvious differences, CUP
Sections du résumé
BACKGROUND
BACKGROUND
Human papillomavirus (HPV) status is the most important predictor of survival in oropharyngeal squamous cell carcinoma (OPSCC). In patients with cervical lymph node metastases of squamous cell carcinoma of unknown origin (CUP
METHODS
METHODS
We assessed a consecutive cohort of CUP
RESULTS
RESULTS
In 32/103 (31%) CUP
CONCLUSIONS
CONCLUSIONS
Despite obvious differences, CUP
Identifiants
pubmed: 37046829
pii: cancers15072167
doi: 10.3390/cancers15072167
pmc: PMC10093301
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Cancer. 2017 Jun 6;116(12):1604-1611
pubmed: 28472822
Oral Oncol. 2020 Apr;103:104608
pubmed: 32163853
PLoS One. 2014 Nov 04;9(11):e110456
pubmed: 25369118
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1024-30
pubmed: 12173016
Head Neck. 2019 Oct;41(10):3700-3711
pubmed: 31301162
Head Neck. 2016 Sep;38(9):1347-53
pubmed: 27002481
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Head Neck. 2021 Dec;43(12):3935-3945
pubmed: 34632677
Int J Cancer. 2019 Sep 15;145(6):1465-1474
pubmed: 30698281
Anticancer Res. 2016 Feb;36(2):487-93
pubmed: 26851001
Cancer Prev Res (Phila). 2019 Jun;12(6):375-382
pubmed: 31003993
Transl Oncol. 2022 Jan;15(1):101300
pubmed: 34864401
Int J Cancer. 2015 Apr 1;136(7):1589-99
pubmed: 25104331
Mol Vis. 2018 Feb 06;24:143-152
pubmed: 29430168
Eur J Cancer. 2017 Mar;74:73-81
pubmed: 28335889
Br J Cancer. 2015 May 26;112(11):1733-6
pubmed: 25950384
Cancer Treat Rev. 2016 Jan;42:24-9
pubmed: 26547133
Eur Arch Otorhinolaryngol. 2003 Sep;260(8):436-43
pubmed: 12684829
Histopathology. 2020 Dec;77(6):989-993
pubmed: 32671903
Ann Oncol. 2018 May 1;29(5):1273-1279
pubmed: 29438466
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Eur Arch Otorhinolaryngol. 2015 Jan;272(1):195-205
pubmed: 24615648
Br J Cancer. 2020 Sep;123(7):1114-1122
pubmed: 32624580
Head Neck. 2013 Jan;35(1):123-32
pubmed: 22034046
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Oral Oncol. 2012 Nov;48(11):1178-84
pubmed: 22739067
Arch Otolaryngol Head Neck Surg. 2008 May;134(5):536-8
pubmed: 18490577
Eur Arch Otorhinolaryngol. 2012 Nov;269(11):2367-71
pubmed: 22588197
Laryngoscope. 2019 Mar;129(3):684-691
pubmed: 30151832
Cancer. 1972 Jun;29(6):1446-9
pubmed: 5031238
Int J Cancer. 2017 Mar 1;140(5):1186-1198
pubmed: 27859245
Int J Cancer. 2013 Jan 1;132(1):63-71
pubmed: 22514107
Am J Ophthalmol. 2016 Oct;170:168-175
pubmed: 27457256
Cancer Treat Rev. 2017 Feb;53:1-9
pubmed: 28027480
Oral Oncol. 2020 Aug;107:104721
pubmed: 32361566
Int J Cancer. 2018 Apr 1;142(7):1361-1368
pubmed: 29159804
Radiother Oncol. 2014 Dec;113(3):324-30
pubmed: 25443497
Clin Transl Radiat Oncol. 2017 Nov 04;8:4-11
pubmed: 29594236
JMIR Cancer. 2021 Oct 13;7(4):e26425
pubmed: 34643534
Laryngoscope. 2021 Sep;131(9):E2534-E2542
pubmed: 33734438